Management of chronic liver diseases and cirrhosis: current status and future directions

• Published in: Chinese medical journal Vol. 133; no. 22; pp. 2647 - 2649
• Main Authors: Xu, Jing-Hang, Yu, Yan-Yan, Xu, Xiao-Yuan
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins 20-11-2020; Lippincott Williams & Wilkins Ovid Technologies; Wolters Kluwer
• Subjects: Ascites; Biopsy; Blood diseases; Esophagus; Etiology; Gastrointestinal surgery; Hepatitis B; Immunoglobulins; Immunotherapy; Infections; Liver diseases; Medical prognosis; China
• ISSN: 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000001084

[1] Globally, the most common etiologies of CLD and cirrhosis are non-alcoholic fatty liver disease (NAFLD), followed by hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol liver disease (ALD) in 2017. [3] Despite the successful HBV vaccination plans in high endemic areas and effective anti-HBV and anti-HCV treatments, the age-standardized prevalence of CLD and cirrhosis caused by HBV and HCV kept rising at a rate of 9.0% and 10.2%, respectively, in the last decade (2007–2017). [...]the age-standardized prevalence of CLD and cirrhosis caused by NAFLD, leading cause of CLD and cirrhosis, increased by 23.5% within the same period. [...]lifestyle modification is still the mainstay of treatment. [7] More emerging medications, such as C-C chemokine receptor types 2 and 5 inhibitor, peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 agonist, vitamin E, and some novel drugs are being studied and potentially provide new solutions.